MedTrace Logo

Evaluation of TXA Prior to Surgery in the Geriatric Hip Fracture Population

NCT03923959 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 283

Last updated 2024-10-10

Study results available
· View outcomes & findings →

Summary

The overall design of the study is a prospective, double-blinded, randomized study in the geriatric hip fracture population comparing those who receive intravenous tranexamic acid prior to incision to those who receive a placebo.

Conditions

  • Hip Fractures

Interventions

DRUG

Tranexamic Acid Injectable Solution

100 cc normal saline mixed with 1g of tranexamic acid in solution

OTHER

Placebo

100 cc normal saline

Sponsors & Collaborators

  • Lancaster General Hospital

    lead OTHER

Principal Investigators

  • Gregory Tocks, DO · Penn Medicine / Lancaster General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2022-12-09
Completion
2022-12-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03923959 on ClinicalTrials.gov